CDX2 and carcinoma: CDX2 expression loss was associated with ascending colon (p = 0.03), partially mucinous adenocarcinoma (p = 0.04), poorly differentiated carcinoma (p < 0.001) and dMMR (Fisher’s Exact Test, p < 0.001).